Article ID Journal Published Year Pages File Type
5928737 American Heart Journal 2013 7 Pages PDF
Abstract
AleCardio will establish whether the PPAR-α/γ agonist aleglitazar improves cardiovascular outcomes in patients with diabetes and high-risk coronary disease.
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Authors
, , , , , , , , , , , , , , , , ,